Publication | Open Access
Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years
15
Citations
39
References
2019
Year
Patient SelectionEligibility CriteriaClinical EndpointAplastic AnemiaMyeloid NeoplasiaHematological MalignancyBone Marrow FailureT-mds Patient ExclusionClinical PopulationHematologyClinical TrialsRandomized Controlled TrialTherapy-related Myelodysplastic SyndromeRadiation OncologyHealth SciencesHealth PolicyKey Points PatientsOutcomes ResearchMalignant Blood DisorderPast 20Medicine
Key Points Patients with t-MDS are underrepresented in clinical trials when taking into account the prevalence of such patients. Eligibility criteria and sponsorship type may contribute to t-MDS patient exclusion.
| Year | Citations | |
|---|---|---|
Page 1
Page 1